Stockreport

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYNEXIS, Inc.  (SCYX) 
Last scynexis, inc. earnings: 11/12 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
PDF In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisComb [Read more]